Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shionogi-ViiV

- PMLiVE

Advair generics and acquisitions to hit GSK in 2019

Earnings to decline as company transforms

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

- PMLiVE

GSK’s Advair Diskus faces first generic in US

Analysts predict around $250m in sales for Wixela Inhub this year

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

- PMLiVE

Pfizer takeover rumour ignites Amarin shares

Fish oil product shows great promise

- PMLiVE

GSK upbeat on its return to oncology market

Zejula signals comeback after four year hiatus

- PMLiVE

GSK and Pfizer to create combined consumer health titan

Spin-out will allow GSK to focus on prescription drugs and vaccines

- PMLiVE

New Pfizer UK leader as Nordkamp moves into European role

Ben Osborn to take on managing director role

- PMLiVE

GSK buys cancer firm Tesaro for $5.1bn

Acquisition re-establishes US commercial operations in oncology

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Daurismo cleared for those too frail for chemo

The handover: Pfizer reshapes itself for a new era

There is a new leader at the world's biggest pharma company - but just how much is set to change at Pfizer?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links